Literature DB >> 3039880

Effect of rifabutin on the phagocytosis and intracellular growth of Mycobacterium intracellulare in mouse resident and activated peritoneal and alveolar macrophages.

V K Perumal, P R Gangadharam, M D Iseman.   

Abstract

In order to understand the discrepant results between in vitro and in vivo activity of rifabutin (LM 427) against Mycobacterium intracellulare, we studied its effects upon the phagocytosis of M. intracellulare by resident and activated mouse peritoneal and alveolar macrophages and upon growth of M. intracellulare inside these cells. Rifabutin (ansamycin, LM 427) had no effect on the viability of resident or activated peritoneal or alveolar macrophages or on the phagocytosis of M. intracellulare by resident peritoneal macrophages. In activated peritoneal and alveolar macrophages, it had a dose-related effect on the phagocytic index and intracellular growth of M. intracellulare. Macrophages from mice pretreated with 10 or 20 mg/kg of rifabutin either orally or intraperitoneally for 4 to 10 days showed inhibition of intracellular growth of M. intracellulare in a dose-related manner. The route of administration or further addition of the drug did not enhance the inhibitory activity of these macrophages. These results indicate that rifabutin has the potential of killing M. intracellulare persisters inside macrophages.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039880     DOI: 10.1164/ajrccm/136.2.334

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Activity of antibiotics against microorganisms ingested by mononuclear phagocytes.

Authors:  P J van den Broek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

3.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

7.  Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model.

Authors:  S K Furney; P S Skinner; J Farrer; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 8.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.